Peterson A M, Meltzer C C, Evanson E J, Flickinger J C, Kondziolka D
Department of Radiology, University of Pittsburgh Medical Center, PA 15213-2582, USA.
Radiology. 1999 Jun;211(3):807-14. doi: 10.1148/radiology.211.3.r99jn48807.
To characterize the magnetic resonance (MR) imaging response of brain metastases after gamma knife stereotactic radiosurgery and determine whether imaging features and tumor response rates correlate with local tumor control and survival.
Serial MR examinations were performed in 48 patients (25 men, 23 women; mean age, 58 years) with 78 lesions. Pretreatment and follow-up enhancing lesion volumes and imaging features were assessed. Rates of response to stereotactic radiosurgery were calculated. Prognostic imaging features affecting local control and survival were analyzed.
Local tumor control was achieved in 66 (90%) of 73 metastases at 20 weeks after stereotactic radiosurgery; 61% maintained local control at 2 years. A homogeneous baseline enhancement pattern and initial good response rate (> 50% lesion volume reduction) predicted local control. Five metastases demonstrated a transient volume increase after treatment. The median survival time after stereotactic radiosurgery was 53 weeks and correlated with systemic disease burden and primary tumor type.
Baseline homogeneous tumor enhancement and initial good response correlate with local control. Initial lesion growth does not preclude local control and may represent radiation-related change. Recognition of these serial MR imaging findings may guide image interpretation and influence treatment in patients with stereotactic radiosurgery-treated metastases.
描述伽玛刀立体定向放射治疗后脑转移瘤的磁共振(MR)成像反应,并确定成像特征和肿瘤反应率是否与局部肿瘤控制及生存相关。
对48例(25例男性,23例女性;平均年龄58岁)有78个病灶的患者进行了系列MR检查。评估了治疗前及随访时强化病灶的体积和成像特征。计算了立体定向放射治疗的反应率。分析了影响局部控制和生存的预后成像特征。
立体定向放射治疗后20周,73个转移瘤中的66个(90%)实现了局部肿瘤控制;2年时61%维持局部控制。均匀的基线强化模式和初始良好反应率(病灶体积缩小>50%)可预测局部控制。5个转移瘤治疗后显示短暂体积增加。立体定向放射治疗后的中位生存时间为53周,与全身疾病负担和原发肿瘤类型相关。
基线肿瘤均匀强化和初始良好反应与局部控制相关。初始病灶生长并不排除局部控制,可能代表与放疗相关的变化。认识这些系列MR成像表现可能指导图像解读并影响接受立体定向放射治疗的转移瘤患者的治疗。